{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:17:49Z","timestamp":1787818669022,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heterogeneous treatment response, characterized by simultaneous regression of some lesions and progression of others within the same patient, is increasingly recognized in metastatic breast cancer (mBC) and may reflect biological heterogeneity. However, this response pattern is not captured by current response assessment frameworks. We aimed to determine the prevalence of heterogeneous treatment response on FDG-PET and mixed response on CT during mBC systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 51 female patients with mBC, treated between November 2017 and November 2025, each undergoing\u2009\u2265\u20092 FDG-PET\/CT scans. Response was assessed according to RECIST 1.1 (CT) and PERCIST (FDG-PET), with using study\u2011specific definitions for heterogeneous\/mixed response informed by literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Heterogeneous metabolic response was observed in 30% of all follow\u2011up FDG\u2011PET examinations (40\/132). These examinations accounted for 60% (40\/67) of the scans classified as progressive metabolic disease (PMD) according to PERCIST. Among CT-examinations, 65 of 141 (46%) follow-up examinations had measurable disease; none of these scans (0\/65, 0%) fulfilled the mixed response criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of mBC undergoing systemic therapy, FDG-PET identified heterogeneous treatment response in a substantial proportion of patients; however, under current PERCIST criteria, these cases were uniformly classified as PMD. In contrast, using RECIST-inspired criteria, CT did not classify any patient as mixed response. These findings suggest that existing frameworks may not fully capture intra-patient response heterogeneity. As heterogeneous response is not an established PERCIST response category, further work is needed to determine how such patterns should be defined and incorporated into future response assessment frameworks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01119-4","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:45:45Z","timestamp":1787762745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification"],"prefix":"10.1186","volume":"26","author":[{"given":"Vilma Landfors","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5099-423X","authenticated-orcid":false,"given":"Kristin","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-8649","authenticated-orcid":false,"given":"Ida","family":"Skarping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"1","key":"1119_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"1119_CR2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"issue":"3","key":"1119_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of Cancer, National Cancer institute of the United States, National Cancer institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1119_CR4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"Jh O, Lodge MA, Wahl RL. Practical PERCIST: a simplified Guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"key":"1119_CR5","doi-asserted-by":"publisher","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S\u201350S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","DOI":"10.2967\/jnumed.108.057307"},{"issue":"7","key":"1119_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2967\/jnumed.115.166629","volume":"57","author":"K Pinker","year":"2016","unstructured":"Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, et al. The impact that number of analyzed metastatic breast cancer lesions has on response assessment by 18F-FDG PET\/CT using PERCIST. J Nucl Med. 2016;57(7):1102\u201304. https:\/\/doi.org\/10.2967\/jnumed.115.166629.","journal-title":"J Nucl Med"},{"key":"1119_CR7","doi-asserted-by":"publisher","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s\u20139s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931.","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"1119_CR8","doi-asserted-by":"publisher","first-page":"103001","DOI":"10.1016\/j.ctrv.2025.103001","volume":"140","author":"G Corso","year":"2025","unstructured":"Corso G, Shen S, Criscitiello C, Mukhtar R, Gamble L, Rocco EG, et al. Invasive lobular carcinoma: strategies and perspectives from the lobular breast cancer research group. Cancer Treat Rev. 2025;140:103001. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103001.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"1119_CR9","doi-asserted-by":"publisher","first-page":"27990","DOI":"10.18632\/oncotarget.15856","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8(17):27990\u201396. https:\/\/doi.org\/10.18632\/oncotarget.15856.","journal-title":"Oncotarget"},{"key":"1119_CR10","doi-asserted-by":"publisher","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, DeSouza Nm NM, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of Cancer consensus recommendation. The Lancet Oncol. 2020;21(1):e18\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1.","DOI":"10.1016\/S1470-2045(19)30718-1"},{"issue":"6","key":"1119_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2967\/jnumed.123.266925","volume":"65","author":"R Moser","year":"2024","unstructured":"Moser R, Pfeiffer S, Cala L, Klein E, Kiechle M, Behzadi ST, et al. Detecting metastatic patterns of oligometastatic breast cancer: a comparative analysis of 18 F-FDG PET\/CT and conventional CT imaging. J Nucl Med. 2024;65(6):845\u201350. https:\/\/doi.org\/10.2967\/jnumed.123.266925.","journal-title":"J Nucl Med"},{"issue":"10","key":"1119_CR12","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1007\/s00330-025-11540-1","volume":"35","author":"M Dioguardi Burgio","year":"2025","unstructured":"Dioguardi Burgio M, Ronot M, Vilgrain V. ESR essentials: assessing the radiological response of liver metastases to systemic therapy\u2014practice recommendations by the European society of gastrointestinal and abdominal radiology. Eur Radiol. 2025;35(10):6516\u201326. https:\/\/doi.org\/10.1007\/s00330-025-11540-1.","journal-title":"Eur Radiol"},{"issue":"11","key":"1119_CR13","doi-asserted-by":"publisher","first-page":"8714","DOI":"10.1007\/s00330-021-07956-0","volume":"31","author":"NM Bruckmann","year":"2021","unstructured":"Bruckmann NM, Kirchner J, Umutlu L, Fendler WP, Seifert R, Herrmann K, et al. Prospective comparison of the diagnostic accuracy of 18F-FDG PET\/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol. 2021;31(11):8714\u201324. https:\/\/doi.org\/10.1007\/s00330-021-07956-0.","journal-title":"Eur Radiol"},{"issue":"12","key":"1119_CR14","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1007\/s00330-021-08041-2","volume":"31","author":"TW Buus","year":"2021","unstructured":"Buus TW, Rasmussen F, Nellemann HM, Logager V, Jensen AB, Hauerslev KR, et al. Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study. Eur Radiol. 2021;31(12):8838\u201349. https:\/\/doi.org\/10.1007\/s00330-021-08041-2.","journal-title":"Eur Radiol"},{"issue":"3","key":"1119_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00259-024-07042-9","volume":"52","author":"SC Vaz","year":"2025","unstructured":"Vaz SC, Groheux D, van Nijnatten T, Antunovic L, Cardoso F, Mottaghy F, et al. Editorial commentary: should \u201cheterogeneous response\u201d be considered as new category for assessing treatment response in patients with breast cancer? Eur J Nucl Med Mol Imag. 2025;52(3):801\u201305. https:\/\/doi.org\/10.1007\/s00259-024-07042-9.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"1119_CR16","doi-asserted-by":"publisher","first-page":"566297","DOI":"10.3389\/fonc.2020.566297","volume":"10","author":"O Humbert","year":"2020","unstructured":"Humbert O, Chardin D. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol. 2020;10:566297. https:\/\/doi.org\/10.3389\/fonc.2020.566297.","journal-title":"Front Oncol"},{"issue":"11","key":"1119_CR17","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/jcm9113483","volume":"9","author":"D Lang","year":"2020","unstructured":"Lang D, Wahl G, Poier N, Graf S, Kiesl D, Lamprecht B, et al. Impact of PET\/CT for assessing response to immunotherapy-A clinical perspective. J Clin Med. 2020;9(11):3483. https:\/\/doi.org\/10.3390\/jcm9113483.","journal-title":"J Clin Med"},{"issue":"7","key":"1119_CR18","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imag. 2022;49(7):2323\u201341. https:\/\/doi.org\/10.1007\/s00259-022-05780-2.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"1119_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.clon.2010.05.021","volume":"22","author":"V Huyge","year":"2010","unstructured":"Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010;22(10):818\u201327. https:\/\/doi.org\/10.1016\/j.clon.2010.05.021.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"1119_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41523-025-00724-z","volume":"11","author":"S Garcia-Recio","year":"2025","unstructured":"Garcia-Recio S, Zagami P, Felsheim BM, Wheless A, Thomas K, Trimarchi R, et al. Understanding metastasis mixed-treatment responses through genomic analyses. NPJ Breast Cancer. 2025;11(1):9. https:\/\/doi.org\/10.1038\/s41523-025-00724-z.","journal-title":"NPJ Breast Cancer"},{"key":"1119_CR21","unstructured":"Behandling av metastaserad br\u00f6stcancer [https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/brostcancer\/vardprogram\/behandling-av-metastaserad-sjukdom2\/#] Access date:2026, June, 21."},{"issue":"2","key":"1119_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer (Oxford, Engl: 1990)"},{"key":"1119_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","volume":"131","author":"MT Milano","year":"2019","unstructured":"Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol. 2019;131:45\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2018.11.022.","journal-title":"Radiother Oncol"},{"issue":"25","key":"1119_CR24","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of Oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. JCO. 2020;38(25):2830\u201338. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"JCO"},{"issue":"supplement 1","key":"1119_CR25","first-page":"280","volume":"53","author":"U Sen","year":"2012","unstructured":"Sen U, Ling H, Chhabra A, Ponzo F, Tiersten A, Friedman K. Mixed metabolic response on PET\/CT in patients with metastatic breast cancer is an early predictor of disease progression. J Nucl Med. 2012;53(supplement 1):280.","journal-title":"J Nucl Med"},{"issue":"2","key":"1119_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10555-022-10023-9","volume":"41","author":"S Kavan","year":"2022","unstructured":"Kavan S, Kruse TA, Vogsen M, Hildebrandt MG, Thomassen M. Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review. Cancer Metastasis Rev. 2022;41(2):433\u201346. https:\/\/doi.org\/10.1007\/s10555-022-10023-9.","journal-title":"Cancer Metastasis Rev"},{"key":"1119_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2017.03.001","volume":"77","author":"M Kosmin","year":"2017","unstructured":"Kosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer (Oxford, Engl: 1990). 2017;77:109\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.001.","journal-title":"Eur J Cancer (Oxford, Engl: 1990)"},{"issue":"Suppl,2","key":"1119_CR28","doi-asserted-by":"publisher","first-page":"103099","DOI":"10.1016\/j.radi.2025.103099","volume":"31","author":"S Murali","year":"2025","unstructured":"Murali S, Sz-Ying Lee W, Wei-En LH, Yi Samuel CJ, Ann Tan JT, Jia Wei B, et al. Exploring the accuracy of whole-body MRI in assessing treatment response in metastatic breast cancer: a narrative review. Radiography (Lond). 2025;31(Suppl,2):103099. https:\/\/doi.org\/10.1016\/j.radi.2025.103099.","journal-title":"Radiogr (Lond)"},{"key":"1119_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.semcancer.2017.04.007","volume":"44","author":"V Appierto","year":"2017","unstructured":"Appierto V, Di Cosimo S, Reduzzi C, Pala V, Cappelletti V, Daidone MG. How to study and overcome tumor heterogeneity with circulating biomarkers: the breast cancer case. Semin Cancer Biol. 2017;44:106\u201316. https:\/\/doi.org\/10.1016\/j.semcancer.2017.04.007.","journal-title":"Semin Cancer Biol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01119-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01119-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:26:43Z","timestamp":1787815603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01119-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01119-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study complied with the Declaration of Helsinki and was approved by either the Ethics Committees at Lund University or by the Swedish Ethical Review Authority (EPN 2016\/417, 2018\/753, 2021\u201305734-02). All participants provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients agreed to the publication of anonymized data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FDG-PET revealed heterogeneous metabolic response in 60% of scans classified as progressive metabolic disease by PERCIST in metastatic breast cancer, whereas paired CT using RECIST\u2011derived criteria detected no mixed responses, highlighting limitations of current response frameworks.","order":3,"name":"Ethics","label":"Critical relevance statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"114"}}